Yeah that's what I was thinking too, just making sure I wasn't missing something (I don't deal with options normally).
TBH today's price is a solid deal. That increase in revenue for the only product on market speaks to its utility.
A lot of fingers in different pies for the company. Revenue for its other tests is likely still far off, but we may begin seeing exosome sales to research groups sooner than people think.
Ann: BARD1 LODGES SPP AND OPTIONS PROSPECTUS, page-9
-
- There are more pages in this discussion • 96 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
